News Recap – Aethlon Medical revels date for its Fourth Quarter and Full Year Fiscal 2016 Investor Call

1337
Nasdaq:AEMD

Aethlon Medical, Inc. (Nasdaq: AEMD), a major maker of immunotherapeutic technologies to fight infectious disease and cancer June 27, 2016 said that plans to host its Q4 and Full-Year Fiscal 2016 investor conference call and webcast on Wednesday, June 29, 2016 at 4:30 p.m. Eastern Time.

Aethlon Medical, Inc. (Nasdaq: AEMD) shares in current trading session were -1.74% down breakeven line and moved at $5.91. To evaluate management effectiveness first thing that comes in mind is how well investors’ fund has been utilized and return on equity is an ideal which for this company was maintained at -146.20%in last twelve months. While another measure return on assets to assess how good was company to utilize assets to generate income, appeared at -115.30%.

This Earning call and webcast will follow the announcement of fiscal 2016 Q4 and full year Earnings.  A recorded version of the call will be obtainable almost two hours after the call at the Investor Relations portion of the company’s website, www.aethlonmedical.com.

Involved participants can also access the archived replay of Aethlon Medical’s Q3 Fiscal 2016 investor conference call webcast at www.aethlonmedical.com in the investor relations section under events & presentations.

Conference Call Details

What: Aethlon’s Fourth Quarter and Full Year Fiscal 2016 Investor Conference Call and Webcast

Date: Wednesday, June 29, 2016

Time: 4:30 p.m. Eastern Time

Live call: 412-317-5442

International: 844-836-8741

Audio Replay: 412-317-0088

Passcode: 10088603

To boost the body’s natural immune defenses, the Aethlon Hemopurifier® removes life-threatening disease targets that are often protected from the immune system and not well talked by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to an exclusive structure that capes these targets from immune detection. At present, the Hemopurifier® is being progressive under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to identify and monitor life-threatening diseases.

 

LEAVE A REPLY